This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lupus Foundation of America (LFA). Introduction to Lupus. LFA web site [online], (2008).
Helmick, C. G. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58, 15–25 (2008).
Genentech. Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus. Genentech web site [online], (2008).
FDA. FDA Warns of Safety Concern Regarding Rituxan in New Patient Population. FDA web site [online], [online], (2006).
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Supplementary information S1 (table)
Products with PDUFA dates missed in 2008* (PDF 221 kb)
Rights and permissions
About this article
Cite this article
Wentworth, J., Davies, C. Systemic lupus erythematosus. Nat Rev Drug Discov 8, 103–104 (2009). https://doi.org/10.1038/nrd2743
Issue Date:
DOI: https://doi.org/10.1038/nrd2743
This article is cited by
-
Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZB×NZW F1 mice via interference with TLR-mediated APC response
Acta Pharmacologica Sinica (2014)
-
BLYS-targeted antibody shows promise in Phase III SLE trial
Nature Reviews Drug Discovery (2009)